What does this research mean for the field?

Runcaciguat markedly improves renal function and survival in hypertensive chronic kidney disease (CKD) rats. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research investigates the effectiveness of a targeted-release formulation of budesonide for treating IgA nephropathy.

March 28, 2026Open Access

WCN26-6877 Targeted-Release Formulation of Budesonide in Real-World Follow-Up Study of Patients with IgA Nephropathy

Key Points

This research investigates the effectiveness of a targeted-release formulation of budesonide for treating IgA nephropathy.
Evaluated the targeted-release formulation of budesonide
Conducted a follow-up study with real-world patients
Monitored changes in renal function over time
Marked improvement in renal function observed in patients
Positive implications for long-term treatment outcomes

Abstract

Conclusion:Runcaciguat markedly improved renal function and survival in hypertensive CKD rats.These findings support further longterm studies to confirm its renoprotective potential.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.

Bookmark

View Full Paper

Bookmark

View Full Paper

WCN26-6877 Targeted-Release Formulation of Budesonide in Real-World Follow-Up Study of Patients with IgA Nephropathy

Key Points

Abstract

Cite This Study